Table 2. Classification of High Grade Pancreatic Neuroendocrine Neoplasms by Secondary Evidence.
| Initial Consensus | Immunohistochemical Abnormalities | Ki67% | Other Histologic Components | Confirmed Classification |
|---|---|---|---|---|
| WD-NET | 50 | G1/G2 WD-NET | WD-NET | |
| WD-NET | DAXX | 70 | G1/G2 WD-NET | WD-NET |
| WD-NET | ATRX | 50 | G1/G2 WD-NET | WD-NET |
| WD-NET | 40 | G1/G2 WD-NET | WD-NET | |
| WD-NET | DAXX | 35 | G1/G2 WD-NET | WD-NET |
| WD-NET | 32 | G1/G2 WD-NET | WD-NET | |
| Ambiguous | 35 | G1/G2 WD-NET | WD-NET | |
| Ambiguous | 65 | G1/G2 WD-NET | WD-NET | |
| Ambiguous | DAXX | 50 | G1/G2 WD-NET | WD-NET |
| Ambiguous | ATRX | 35 | G1/G2 WD-NET | WD-NET |
| Ambiguous | DAXX | 30 | G1/G2 WD-NET | WD-NET |
| Ambiguous | 60 | G1/G2 WD-NET | WD-NET | |
| Ambiguous | ATRX | 40 | WD-NET | |
| Ambiguous | DAXX | 80 | G1/G2 WD-NET | WD-NET |
| Ambiguous | DAXX | 49 | G1/G2 WD-NET | WD-NET |
| Ambiguous | 38 | G1/G2 WD-NET | WD-NET | |
| Ambiguous | 60 | G1/G2 WD-NET | WD-NET | |
| Ambiguous | 50 | G1/G2 WD-NET | WD-NET | |
| Ambiguous | 70 | G1/G2 WD-NET | WD-NET | |
| Ambiguous | p53/Rb | 88 | PD-NEC | |
| Ambiguous | p53/SMAD4 | 38 | Ductal adenocarcinoma | PD-NEC |
| Ambiguous | p53/Rb | 70 | PD-NEC | |
| Ambiguous | p53/Rb | 85 | PD-NEC | |
| Ambiguous | p53 | 60 | PD-NEC | |
| Ambiguous | 70 | Undetermined | ||
| PD-NEC-LCC | DAXX | 66 | G1/G2 WD-NET | WD-NET |
| PD-NEC-LCC | Rb | 44 | PD-NEC | |
| PD-NEC-LCC | 26 | Ductal adenocarcinoma | PD-NEC | |
| PD-NEC-SCC | p53 | 80 | Ductal adenocarcinoma | PD-NEC |
| PD-NEC-SCC | Rb | 90 | PD-NEC | |
| PD-NEC-SCC | p53/Rb | 94 | Ductal adenocarcinoma | PD-NEC |
| PD-NEC | Rb | 84 | PD-NEC | |
| PD-NEC | p53 | 88 | PD-NEC |